Classification of ET and PV according to JAK2-V617F expression levels
. | ET JAK2-V617F status . | . | . | . | PV JAK2-V617F status . | . | . | . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | Negative (P) . | All positive (P) . | Less than 25% (P) . | 25% to 40% (P) . | 25% to 40% (P) . | 41% to 74% . | 75% or more (P) . | All positive . | ||||||
| No. of patients | 17 | 42 | 31 | 11 | 12 | 26 | 20 | 58 | ||||||
| JAK2-WT/100 ABL | 408 ± 421 | 377 ± 373 | 306 ± 282 | 600 ± 549 (.028*) | 459 ± 323 | 316 ± 274 | 148 ± 130 | 289 ± 266 | ||||||
| Total JAK2/100 ABL | 408 ± 421 | 495 ± 533 | 363 ± 338 | 896 ± 837 (.005*) | 700 ± 514 (.947†) | 764 ± 614 | 1120 ± 773 | 857 ± 666 | ||||||
| Leukocyte count, × 109/L | 9.4 ± 3.0 (.029†) | 10.4 ± 3.7 (.327‡) | 9.7 ± 3.2 (.023†) | 12.7 ± 4.6 | 11.2 ± 4.4 (.510†) | 10.3 ± 2.0 | 16.2 ± 5.2 | 12.0 ± 4.6 | ||||||
| Hematocrit | 0.39 ± 0.05 | 0.42 ± 0.04 (.015‡) | 0.42 ± 0.04 (.013‡) | 0.42 ± 0.05 (.132‡) | 0.55 ± 0.05 (.001†) | 0.58 ± 0.5 | 0.60 ± 0.04 (.033§) | 0.58 ± 0.05 | ||||||
| Hemoglobin level, g/L | 131 ± 14 | 140 ± 15 (.038‡) | 140 ± 15 (.048‡) | 142 ± 18 | 179 ± 19 (.001†) | 184 ± 18 | 193 ± 16 (.033§) | 186 ± 18 | ||||||
| Platelet count, × 109/L | 977 ± 347 | 785 ± 198 (.010‡) | 759 ± 228 (.012‡) | 797 ± 200 | 475 ± 226 (.003†) | 515 ± 175 | 400 ± 187 | 466 ± 197 | ||||||
| % positive for EEC | 6 | 33 | 32 | 36 | 91 (.016†) | 84 | 89 | 91 | ||||||
| % positive for EMC | 60 | 93 (.007<11) | 93 (.017<11) | 90 | 70 | 57 | 64 | 63 | ||||||
. | ET JAK2-V617F status . | . | . | . | PV JAK2-V617F status . | . | . | . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | Negative (P) . | All positive (P) . | Less than 25% (P) . | 25% to 40% (P) . | 25% to 40% (P) . | 41% to 74% . | 75% or more (P) . | All positive . | ||||||
| No. of patients | 17 | 42 | 31 | 11 | 12 | 26 | 20 | 58 | ||||||
| JAK2-WT/100 ABL | 408 ± 421 | 377 ± 373 | 306 ± 282 | 600 ± 549 (.028*) | 459 ± 323 | 316 ± 274 | 148 ± 130 | 289 ± 266 | ||||||
| Total JAK2/100 ABL | 408 ± 421 | 495 ± 533 | 363 ± 338 | 896 ± 837 (.005*) | 700 ± 514 (.947†) | 764 ± 614 | 1120 ± 773 | 857 ± 666 | ||||||
| Leukocyte count, × 109/L | 9.4 ± 3.0 (.029†) | 10.4 ± 3.7 (.327‡) | 9.7 ± 3.2 (.023†) | 12.7 ± 4.6 | 11.2 ± 4.4 (.510†) | 10.3 ± 2.0 | 16.2 ± 5.2 | 12.0 ± 4.6 | ||||||
| Hematocrit | 0.39 ± 0.05 | 0.42 ± 0.04 (.015‡) | 0.42 ± 0.04 (.013‡) | 0.42 ± 0.05 (.132‡) | 0.55 ± 0.05 (.001†) | 0.58 ± 0.5 | 0.60 ± 0.04 (.033§) | 0.58 ± 0.05 | ||||||
| Hemoglobin level, g/L | 131 ± 14 | 140 ± 15 (.038‡) | 140 ± 15 (.048‡) | 142 ± 18 | 179 ± 19 (.001†) | 184 ± 18 | 193 ± 16 (.033§) | 186 ± 18 | ||||||
| Platelet count, × 109/L | 977 ± 347 | 785 ± 198 (.010‡) | 759 ± 228 (.012‡) | 797 ± 200 | 475 ± 226 (.003†) | 515 ± 175 | 400 ± 187 | 466 ± 197 | ||||||
| % positive for EEC | 6 | 33 | 32 | 36 | 91 (.016†) | 84 | 89 | 91 | ||||||
| % positive for EMC | 60 | 93 (.007<11) | 93 (.017<11) | 90 | 70 | 57 | 64 | 63 | ||||||
Plus-minus values indicate mean ± SD.
∥Compared with negative ET, Fisher exact test. A P values less than .05 was considered statistically significant.
Compared with ET with less than 25% JAK2-V617F.
Compared with ET with 25% to 40% JAK2-V617F.
Compared with negative ET.
Compared with PV with 25% to 40% JAK2-V617F, Mann-Whitney rank sum test.